Product information and disease descriptionProduct description
Phase of product development
23 evidence topics · 19 sources
Regulatory status: Under review; NDA submitted April 2026, PDUFA target action date April 2027
Launch
No evidence found.
NDA submission, April 2026
FDA acceptance of the NDA and PDUFA target action date, July 2026
NDA review under conventional FDA procedures and timeline
EMA marketing authorization application submitted and validated, October 2026
FDA orphan drug designation, November 2023
| Field | Quoted record |
|---|---|
| Generic name | “varegacestat” |
| Date designated | “11/02/2023” |
| Orphan designation | “Treatment of desmoid tumors” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Immunome, Inc.” |
EMA orphan designation: company statement of July 2025 for desmoid tumors
EMA orphan designation: EMA register entry of 22 August 2025 for soft tissue sarcoma
| Field | Quoted record |
|---|---|
| Active substance | “varegacestat” |
| Intended use | “Treatment of soft tissue sarcoma” |
| Orphan designation status | “Positive” |
| EU designation number | “EU/3/25/3127” |
| Date of designation | “22/08/2025” |
| Sponsor | “Somerville Development Partners B.V.” |